Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camostat and bicalutamide for COVID-19
NCT04652765Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of camostat mesilate and bicalutamide in coronavirus disease 2019 (COVID-19), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2021; status: terminated.
02
Drugs
camostat mesilatebicalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04652765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652765.